Ballicules.com

Suvorexant

BELSOMRA

What it isDual OX1 and OX2 orexin-receptor antagonist; insomnia.

Why this oneAs the first dual orexin antagonist, it established a non-GABAergic option for both sleep onset and maintenance.

What limits itNext-day somnolence requires adequate sleep time; CYP3A4 interactions, falls, and Schedule IV misuse risk remain.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Insomnia (sleep onset and/or maintenance)Adults10 mg QHS10 mg QHS20 mg QHS
Insomnia, with moderate CYP3A inhibitorAdults5 mg QHS5 mg QHS10 mg QHS

Renal No adjustment needed

Hepatic Mild-moderate: no adjustment; severe: not recommended

No more than once per night; obese women have higher exposure — consider before dose increase

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Insufficient human data; animal studies showed decreased maternal/fetal weight

Lactation Present in breast milk at low concentrations (relative infant dose <1%)

NO BOXED WARNINGS

Principal riskNext-day somnolence; allow seven hours before waking

Cost, est. cash$300–$2,500/month

Generic entry2029 est.

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability3 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityNext-day somnolence, abnormal sleep behaviors and additive CNS depression.

Mechanism of action: Suvorexant ballicule

Suvorexant ballicule: receptor binding, kinetics and half-life diagram

Open Suvorexant in the interactive console ↗

Memory aids: mascots and interaction avatars

Suvorexant BELSOMRA mascot mnemonic cartoon
“(Bell o’ somnolence) S.U.V. wrecks it”
Blocks orexin, allowing sleep
Suvorexant CYP3A4 substrate avatar
CYP3A4 substrate

Open Suvorexant in the interactive console ↗